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Background: The effect of breast cancer subtype on margin status after lumpectomy remains unclear. This study
aims to determine whether approximated breast cancer subtype is associated with positive margins after
lumpectomy, which could be used to determine if there is an increased risk of developing local recurrence (LR)
following breast-conserving surgery.
Methods: We studied 1,032 consecutive patients with invasive cancer who received lumpectomies and cavity
margin (CM) assessments from January 2003 to November 2012. The following data were collected: patient age,
cT stage, pT stage, grade, status of CM, lymph node status, menopausal status, ER, PR, HER-2, and Ki67, as well as
the presence of extensive intraductal component (EIC) and lymphovascular invasion (LVI). A χ2 test was used to
compare categorical baseline characteristics. Univariate and multivariate logistic regression analyses were performed
to evaluate associations between pathologic features of CM status. Kaplan-Meier actuarial cumulative rates of LR
(ipsilateral in-breast) were calculated.
Results: A total of 7,884 pieces of marginal tissue were collected from 1,032 patients, and 209 patients had positive
CMs. Of the patients tested, 52.3% had luminal A subtype, 14.9% were luminal B, 12.8% were luminal-HER-2, 8.1%
were HER-2 enriched, and 11.8% were triple negative. Univariate analysis showed that EIC (P <0.001), LVI (P = 0.026),
pN stage (N1 vs. N0: P = 0.018; N3 vs. N0: P <0.001), and luminal B (P = 0.001) and HER-2 (P <0.001) subtypes were
associated with positive CMs. Multivariable analysis indicated that only EIC (P <0.001), pN stage (P = 0.003), and
HER-2 subtype (P <0.001) were significantly correlated with positive CMs. On multivariable analysis, HER-2 subtype
was an independent prognostic factor in LR (P = 0.031).
Conclusions: The HER-2 subtype was the predictive factor most associated with positive CMs and an independent
prognostic factor for LR. This result suggests that the increased risk of LR in HER-2 breast cancer is due to an
increased microscopic invasive tumor burden, which is indicated by margin status after lumpectomy.
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DNA microarray profiles have been used to classify
breast tumors into distinct biologic subtypes [1,2]. This
testing may not often be feasible in a clinical setting, and
these subtypes can be approximated by the expression of
immunohistochemically-defined biological markers, such
as the estrogen receptor (ER), the progesterone receptor
(PR), and the human epidermal growth factor receptor 2
(HER-2), to classify tumors as luminal A (ER+ or PR+
and HER-2−), luminal B (ER+ or PR+ and HER-2+), HER-
2+ (ER− and PR− and HER-2+), or triple-negative (TN)
(ER− and PR− and HER-2−) subtypes [3]. Most reports
show that the luminal A subtype is associated with the
best prognosis, whereas significantly worse prognoses have
been observed for the HER-2 and TN subgroups [4-6].
Randomized trials have validated breast-conserving
surgery (BCS) as the standard treatment for early stage
breast cancer (BC) [7,8]. Minimizing local recurrence
(LR) in the breast is very important in clinical settings
because LR is associated with reduced survival and emo-
tional distress [9]. The status of the surgical margin has
been shown to be an independent predictor of LR
[10,11]. In a review including 34 related studies, LR was
increased in cases involving a persistent, positive margin
[12]. Negative margins should be achieved during BCS
as recommended by the National Comprehensive Can-
cer Network guidelines.
Many studies have demonstrated that patients with
HER-2 overexpression and TN BCs are at increased risk
of developing LR following BCS [6,13,14]. Does the
higher risk of LR in the two subtypes result from an
increased microscopic invasive tumor burden that could
be indicated by margin status after lumpectomy? We
have no definite answer at present. Positive margins
were reported to be significantly associated with large
tumor size, young age, positive nodes, presence of lym-
phovascular invasion (LVI), and presence of an extensive
intraductal component (EIC) [15-17]. In addition to the
above analyzed clinical and pathologic variables, molecu-
lar phenotype may be a relevant factor of positive margins.
The purpose of this study was to determine whether BC
subtype approximation is associated with positive mar-
gins after initial lumpectomy and the extent of initial




We retrospectively reviewed the clinical and histopatho-
logic data of 1,032 consecutive women ranging from 22
to 89 years (mean 48.2 years, median 47 years) at the
time of diagnosis with clinical stage I or II invasive BC
deemed suitable for BCS treated with lumpectomy and
cavity margin (CM) excision between January 2003 andNovember 2012 in our center. The following data were
included in the analysis: patient age, clinical T stage,
pathological T stage, tumor grade, CM status, lymph
nodes status, menopausal status, ER, PR, HER-2, and
Ki67, as well as the presence of EIC and LVI (Table 1).
Patients treated with prior neoadjuvant chemotherapy,
endocrine therapy or radiation therapy to the breast or
chest wall were excluded from the analysis, and patients
with synchronous bilateral BC, more than one malignancy
in one breast, or the presence of a non-palpable tumor
were also excluded. We obtained approval for this study
from the Institutional Review Board at Sun Yat-sen
Memorial Hospital.
Surgical and pathological considerations
There are two primary approaches that are currently
used for surgical margin assessment after initial lumpec-
tomy: lumpectomy margin [18,19] (LM, excision of the
specimen containing the tumor) and CM (breast tissue
sampled from resection bed cavity) [20,21]. CMs are in-
creasingly used for a comprehensive assessment of mar-
gin status, avoiding an unnecessary second operation in
nearly half of patients to achieve negative margins and
with the belief that these represent true margins and
supersede LMs [20-23]. In our center, CM excision was
employed as a routine part of lumpectomies. Physical
examination, ultrasound, mammogram, and occasionally
magnetic resonance imaging were used for BC diagnosis.
For the lumpectomy, 1 cm of macroscopically normal
tissue was removed to ensure that the margins of the re-
moved specimens would be tumor free. The superficial
and deep margins of the excision extended up to the
skin and to the pectoralis fascia. Following excision of
the main tumor, seven to nine rectangular CMs
[length × width × thickness: (5–10 mm) × (5–10 mm) ×
(5 mm)] within the perimeter of the lumpectomy resec-
tion cavity were excised in a clockwise direction at the
time of the lumpectomy, as reported previously [23].
After the resection of each CM, a silk suture was
stitched to mark its location within the lumpectomy cav-
ity, and CMs were submitted separately for histopatho-
logic analysis. CMs were defined as positive when tumor
cells were observed, regardless of whether they were
carcinoma in situ or microscopic invasive carcinoma
and independent of their distance from the true margin.
Patients were recommended for further surgery for re-
excision or mastectomy when one or more positive CMs
were found. This procedure was well described in our
prior study [24].
Classification of subtypes
Breast cancers expressing high levels of Ki67 have been
found to be associated with worse outcomes [25,26]. In
2009, Cheang et al. [27] determined that the optimal





























Carcinoma in situ 87 8.4
Invasive carcinoma 122 11.8
Presence of LVI 114 11.9
Presence of EIC 102 9.9
ER or PR positive 826 80.0
HER-2 positive 216 12.0
Histological subtype
Invasive ductal carcinoma 805 78.0
Presence of DCIS component 83 8.0
Invasive lobular carcinoma 29 2.8
Other 115 11.2
Breast cancer subtype
Luminal A 540 52.3
Luminal B 154 14.9
Luminal-HER-2 132 12.8
HER-2 positive 84 8.1
TN 122 11.8
EIC, Extensive intraductal component; LVI, Lymphovascular invasion; ER,
Estrogen receptor; PR, Progesterone receptor; HER-2, Human epidermal growth
factor receptor 2; DCIS, Ductal carcinoma in situ; IDC, Invasive ductal carcinoma;
TN, Triple-negative.
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distinguishing luminal B from luminal A subtype. Based
on this classification, the 12th St. Gallen International
Breast Cancer Conference (2011) Expert Panel adopted a
new immunohistochemical (IHC) classification of intrin-
sic subtypes, following application of the Ki67 labeling
index using 14% as the cutoff value [28]. Therefore, bio-
logical cancer subtypes are approximated as follows: lu-
minal A (ER+ or PR+ and HER-2−, Ki67 < 14%), luminal
B (ER+ or PR+ and HER-2−, Ki67 ≥ 14%), luminal-HER-2
(ER+ or PR+ and HER-2+), HER-2 (ER− and PR− and
HER-2+), and triple-negative (TN, ER− and PR− and
HER-2−). This new classification was employed in our
study. ER and PR statuses were determined using IHC
staining. Positive ER or PR status was defined as ≥10%
of tumor cell nuclei showing specific staining. An inten-
sity of 0 to 1+ was considered HER-2 negative. Tumors
were considered HER-2 positive if they were scored as
3+ by IHC or as 2+ by IHC and confirmed by fluores-
cence in situ hybridization amplification [29]. Grading of
tumors was based on the modified Black’s nuclear grading
system [30].
Statistical analysis
A χ2 test was used to compare baseline characteristics
among categorical variables. Margin status were ana-
lyzed by using univariate and multivariate logistic regres-
sion models. Associations with LR (ipsilateral in-breast)
after BCS were evaluated using univariate and multivari-
ate Cox proportional hazards regression models and
summarized with hazard ratios and 95% confidence in-
tervals (CIs). Kaplan-Meier actuarial cumulative rates of
LR were calculated. All statistical tests were two-sided
and considered statistically significant at 0.05. We per-
formed all data analysis using SPSS 19.0 for Windows.
Results
Baseline characteristics stratified according to breast
cancer (BC) subtype
There were significant differences between the five BC
subtypes in the distribution of age (P = 0.030), histo-
logical subtype (P <0.001), cT stage (P = 0.034), pT
stage (P = 0.006), grade (P <0.001), and EIC (P <0.001;
Additional file 1: Table S1). In the study, we found that
compared to the other BC subtypes, the TN subtype was
most commonly observed at an age of 36 to 50 years,
and the HER-2 subtype was commonly observed at an
age of >50 years and frequently exhibited EIC, larger
tumor size, and positive margins.
Baseline characteristics stratified according to age
quartile
There were significant differences among the three age
quartiles in the distribution of BC subtype (P = 0.030),
Table 3 Univariate analysis: clinicopathological features
correlated with positive cavity margins
Variable n OR (95% CI) P value
BC subtype
Luminal B vs. luminal A 154 2.03 (1.34–3.08) 0.001
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Table S2). Compared to older patients, younger women
more frequently had BC exhibiting LVI. To our surprise,
in our study, older women more frequently had BC with
larger tumors.Luminal-HER-2 vs. luminal A 132 1.43 (0.89–2.28) 0.139
HER-2 vs. luminal A 84 3.45 (2.11–5.63) <0.001
Triple-negative vs. luminal A 122 0.60 (0.33–1.12) 0.110
Grade
G2 vs. G1 590 0.98 (0.56–1.73) 0.947
G3 vs. G1 354 0.99 (0.55–1.79) 0.977
Histological subtype
Presence of DCIS vs. IDC 83 2.42 (1.50–3.90) <0.001
ILC vs. IDC 29 1.83 (0.82–4.09) 0.142
Others vs. IDC 115 0.39 (0.20–0.76) 0.006
Menopausal status
Post- vs. pre- 379 0.98 (0.71–1.34) 0.894Rate of positive cavity margins (CMs) by age quartile and
breast cancer (BC) subtype
Table 2 provides an analysis of positive CMs by age quar-
tile and BC subtype. We did not see any differences in
positive CMs by BC subtype in the age group ≤35 years
(P = 0.204). In contrast, there were significant differ-
ences in positive CMs between the two older age quar-
tiles, middle age (P <0.001) and >50 years (P = 0.001). In
the middle age quartile, 40.6% and 42.9% of patients
with luminal B and HER-2 subtypes, respectively, had
positive CMs, which was higher than in older age quartile.
In the >50 years age group, only patients with HER-2
subtypes had higher CM positivity.cT stage
T2/3 vs. T1 398 0.97 (0.71–1.34) 0.873
EIC 102 2.77 (1.80–4.27) <0.001
LVI 114 1.64 (1.06–2.55) 0.026
Age
~50 vs. ≤35 527 1.71 (0.97–3.02) 0.063
>50 vs. ≤35 395 1.35 (0.75–2.44) 0.311
pN stage
N1 vs. N0 209 1.56 (1.08–2.25) 0.018
N2 vs. N0 50 1.03 (0.49–2.18) 0.932
N3 vs. N0 30 6.15 (2.92–12.98) <0.001
pT stage
T2 vs. T1 271 1.17 (0.82–1.66) 0.382
Positive CMs include DCIS and invasive carcinoma.
EIC, Extensive intraductal component; LVI, Lymphovascular invasion; ER,
Estrogen receptor; PR, Progesterone receptor; HER-2, Human epidermal growth
factor receptor 2; DCIS, Ductal carcinoma in situ; IDC, Invasive ductal carcinoma;
ILC, Invasive lobular carcinoma; TN, Triple-negative.Univariate and multivariate analysis: clinicopathological
features associated with positive margins
By univariate analysis, age, cT stage, menopausal status,
and tumor grade were not statistically significantly cor-
related with positive CMs. However, the presence of EIC
(OR = 2.77, 95% CI: 1.80–4.27, P <0.001), LVI (OR =
1.64, 95% CI: 1.06–2.55, P = 0.026), pN stage (N1 vs. N0:
OR = 1.56, 95% CI: 1.08–2.25, P = 0.018; N3 vs. N0:
OR = 6.15, 95% CI: 2.92–12.98, P <0.001), histological
subtype (presence of ductal carcinoma in situ (DCIS)
component vs. IDC: OR= 2.42, 95% CI: 1.50–3.90, P <0.001)
and BC subtype (luminal B vs. luminal A: OR = 2.03, 95%
CI: 1.34–3.08, P = 0.001; HER-2 vs. luminal A: OR = 3.45,
95% CI: 2.11–5.63, P <0.001, Table 3) had a statistically
significant correlation with positive CMs.
Only significant variables in the univariate analysis
were applied to the multivariate analysis with logistic
regression model. By multivariate analysis, EIC (OR =
2.58, 95% CI: 1.54–4.32, P <0.001), pN stage (N3 vs.
N0: OR = 3.92, 95% CI: 1.60–9.62, P = 0.003), and the
HER-2 BC subtype (HER-2 vs. luminal A: OR = 2.60, 95%
CI: 1.48–4.57, P <0.001; Table 4) were significantly corre-









≤35 (n = 110) 18.0 20.0
36–50 (n = 527) 17.8 40.6
>50 (n = 395) 14.5 18.3
Positive CMs include ductal carcinoma in situ and invasive carcinoma.LR based on breast cancer (BC) subtype
After a median follow-up of 63 months, a total of 831
patients who underwent successful conservative surgery
with available follow-up records were reviewed for sur-
vival analysis. There were 32 LRs (ipsilateral in breast).










0.0 22.2 0.0 0.204
24.7 42.9 12.2 <0.001
23.4 42.5 11.8 0.001
Table 4 Multivariate analysis: clinicopathological features correlated with positive cavity margins
Variable OR 95% CI P value
A. Positive CMs including DCIS and invasive carcinoma
EIC 2.58 1.54–4.32 <0.001
Luminal B vs. luminal A 1.22 0.73–2.04 0.456
Luminal-HER-2 vs. luminal A 1.08 0.63–1.86 0.774
HER-2 vs. luminal A 2.60 1.48–4.57 <0.001
Triple-negative vs. luminal A 0.71 0.37–1.39 0.320
N1 vs. N0 1.43 0.92–2.20 0.109
N2 vs. N0 1.17 0.51–2.70 0.706
N3 vs. N0 3.92 1.60–9.62 0.003
B. Positive CM including DCIS only
EIC 4.50 2.59–7.84 <0.001
Luminal B vs. luminal A 2.42 1.26–4.67 0.008
Luminal-HER-2 vs. luminal A 2.06 1.07–3.99 0.032
HER-2 vs. luminal A 5.58 2.89–10.77 <0.001
Triple-negative vs. luminal A 0.64 0.22–1.87 0.414
C. Positive CM including invasive cancer only
Presence of DCIS component vs. IDC 2.19 1.04–4.63 0.040
ILC vs. IDC 2.82 1.10–7.23 0.031
Other vs. IDC 0.75 0.33–1.70 0.488
pN stage
N1 vs. N0 2.15 1.30–3.53 0.003
N2 vs. N0 1.41 0.53–3.77 0.490
N3 vs. N0 8.42 3.54–20.05 <0.001
DCIS, Ductal carcinoma in situ; IDC, Invasive ductal carcinoma; EIC, Extensive intraductal component; ILC, Invasive lobular carcinoma.
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A subgroup, the 5-year cumulative incidence of LR was
3.9% (95% CI: 0.3–7.5%), compared with 4.4% (95% CI:
0–10.5%) for luminal B, 4.7% (95% CI: 0–10%) for
luminal-HER-2, 13.4% (95% CI: 0–27.0%) for HER-2,
and 8.8% (95% CI: 1.5–16.1%) for TN patients, respect-
ively (Figure 1).
On univariable analysis, young age (36–50 vs. ≤35, P =
0.042), tumor size (T2 vs. T1, P = 0.014), positive nodes
(LN+ vs. LN−, P = 0.032) and HER-2 subtype (HER-2 vs.
luminal A, P = 0.016) were independently associated with
increased risk of LR (Table 5). A multivariate Cox model
revealed independent prognostic roles for tumor size (T2
vs. T1, P = 0.001), node status (LN+ vs. LN−, P = 0.044),
and HER-2 subtype (HER-2 vs. luminal A, P = 0.031) in
LR (Table 6).
Discussion
In this study, we determined whether BC subtype, as
approximated by ER, PR, HER-2, and Ki67, was asso-
ciated with positive CMs of 1,032 consecutive women
who underwent lumpectomies for early stage invasive BC.
Compared to all other subtypes, the HER-2 positivesubtype was an independent predictor of positive CMs
(OR = 2.60, P <0.001) and an independent prognostic
factor for LR (P = 0.016).
Many reports have shown that patients with the HER-
2 subtype have an increased risk for LR after BCS and
radiotherapy (RT) [6,14]. In our study we found that
HER-2 positive patients had a significantly higher recur-
rence risk, which is consistent with above studies. Ran-
domized trials have demonstrated that the addition of
trastuzumab to chemotherapy decreases LR by approxi-
mately 50% compared to treatment with chemotherapy
alone [29]. The mechanisms underlying the high rate of
LR in patients with the HER-2 subtype have not been
conclusively determined. In a study, HER-2 status was
reported to be the only primary tumor characteristic that
correlated with the presence of circulating tumor cells
[31]. Some groups have found that circulating tumor
cells in operable BC patients are associated with worse
prognosis [32]. In another study, patients with the HER-
2 subtype were found to be more likely to have multi-
centric disease [33]. It was also reported that patients
with the HER-2 subtype may be relatively resistant to










Figure 1 Cumulative incidence of local recurrence (ipsilateral in breast) by breast cancer subtype.
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HER-2 subtype was associated with an increase in posi-
tive CMs may lead to interpreting HER-2 BC with multi-
centric disease, which would result in increased residual
microscopic tumors and higher LR to some extent. The
follow-up results in our study showed that the HER-2
positive cancer had the highest LR, and maybe it is a
reasonable verification of the above theory.
In a previous study, luminal BCs were reported to have
a better prognosis [4,5]. Interestingly, increased LR with
the luminal B subtype among young women after BCS
has been reported [35,36]. In the current study, 40.6% of
patients between the ages of 36 to 50 years with the
luminal B subtype had positive CMs, which was higher




HR (95% CI) P
~50 vs. ≤35 0.33 (0.12–0.96) 0.042
≥50 vs. ≤35 0.78 (0.28–2.08) 0.589
T2 vs. T1 1.22 (1.04–1.44) 0.014
LN+ vs. LN− 2.41 (1.08–5.38) 0.032
G3 vs. G1 1.90 (0.95–3.80) 0.069
Luminal B vs. luminal A 0.59 (0.12–2.94) 0.517
Luminal-HER-2 vs. luminal A 1.86 (0.46–7.43) 0.381
HER-2 vs. luminal A 4.04 (1.30–12.54) 0.016
TN vs. luminal A 2.30 (0.77–6.87) 0.137with the luminal A subtype as the baseline, the lu-
minal B subtype was associated with an increased rate
of positive CMs, with an odds ratio of 2.03 (95% CI:
1.34–3.08, P = 0.001). This finding may partially ex-
plain the increased LR with the luminal B subtype. The
mechanisms are still not well understood and need further
study.
In our study, the TN subtype had a low rate of positive
CMs, and the result did not seem to coincide with the
higher LR of the TN subtype reported by most papers
[4,37,38]. We observed the clinicopathologic features of
the TN subgroup in the present study and found that this
low rate of positive CMs may be related to the fact that
most TN patients had T1 stage tumors (60.7%), less pres-
ence of LVI (TN vs. HER-2: 10.7% vs. 14.3%), and EIC




HR (95% CI) P
~50 vs. ≤35 0.384 (0.13–1.15) 0.086
≥50 vs. ≤35 1.031 (0.36–2.96) 0.955
T2 vs.T1 1.392 (1.15–1.69) 0.001
LN+ vs. LN− 2.348 (1.02–5.39) 0.044
Luminal B vs. luminal A 0.368 (0.07–1.99) 0.245
Luminal-HER-2 vs. luminal A 1.662 (0.40–6.84) 0.482
HER-2 vs. luminal A 3.650 (1.13–11.80) 0.031
TN vs. luminal A 2.025 (0.64–6.41) 0.230
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neoadjuvant chemotherapy and would have thus been ex-
cluded from our study. This finding may reflect selection
bias, but we have performed multivariate analyses to
adjust for the confounding factors.
Our univariate analysis showed that the BC subtype, the
presence of EIC or LVI, histopathology subtype, and pN
stage were significantly associated with positive CMs. This
result was not completely consistent with a previous study
[20]. Cao et al. [20] reported that younger patient age,
higher number of positive LMs, higher tumor grade, and
the presence of EIC were predictive of residual carcinoma
in CM specimens. In our study, age and high tumor grade
were not predictive factors of positive CMs. Several previ-
ous studies have also demonstrated that the presence of
EIC [17,20] and larger tumor size [22,39] were predictive
factors for positive CMs. So far, we have only found one
paper, reported by Sioshansi et al. [39], that was specific-
ally looking for associations of different BC subtypes with
the risk of residual tumors. Sioshansi et al. [39] showed
that age (P = 0.003), tumor size (P <0.001), LVI (P = 0.007),
nodal status (P <0.001), and TN subtype (P = 0.006) were
associated with an elevated risk of residual invasive cancer
by univariate analysis [39]. In our univariate analysis, EIC
(P <0.001) was also an important predictive component
of positive CMs, and this was not shown in the previ-
ous study. Using multivariable analysis, only nodal status
(OR = 3.06, 95% CI: 1.77–5.30, P <0.001), TN status (TN
vs. non-TN, OR = 3.28, 95% CI: 1.56–6.89, P = 0.02), and
tumor size (tumor size >2.0 cm vs. <1.0 cm, OR = 3.49,
95% CI: 1.65–7.38, P = 0.001) maintained statistical signifi-
cance on multivariate analysis [39]. However, tumor size
was not a significant predictive factor associated with
positive CMs in our multivariate analysis. EIC (OR = 2.58,
95% CI: 1.53–4.32, P <0.001), pN stage (N3 vs. N0: OR =
3.92, 95% CI: 1.60–9.62, P = 0.003), and HER-2 subtype
(HER-2 vs. luminal A: OR = 2.60, 95% CI: 1.48–4.57,
P <0.001) were significantly correlated with positive CMs.
The difference between associated BC subtypes may be
due to the following: i) Classification by different immu-
nohistochemical markers. In previous studies, approxi-
mated molecular phenotypes were defined by ER, PR, and
HER-2, which was different from our new classification.
On the basis of recent data suggested by the 12th St.
Gallen International Breast Cancer Conference (2011)
Expert Panel, the Ki67 index was used in our study, which
additionally discriminated partial luminal B patients from
luminal A patients. The use of the Ki67 index is unique to
this study. ii) Distribution of BC subtypes. Sioshansi et al.
[39] reported that 73.5% of patients in their study were lu-
minal A, 9.5% were luminal B, 4.5% were HER-2 enriched,
and 12.5% were TN. In our study, 52.3% were luminal A,
14.9% were luminal B, 12.8% were luminal-HER-2, 8.0%
were HER-2, and 11.8% were TN.Among different age groups, positive rate of CMs in
different molecular subtypes is not clear yet. We ana-
lyzed positive rates of CMs (including invasive cancer
and carcinoma in situ) by age quartile and BC subtype
in the current study. Women aged ≤35 years with BC
are reported to have a poor prognosis and for most
women, and menopause happens around age 50. Ac-
cording to this, we divided patients into three groups. In
the youngest age quartile (≤35 years), the positive CM
rate demonstrated no significant difference (P = 0.204).
In contrast, the quartile containing ages 36 to 50 years
had positive CM rates of 40.6% and 40.9% in luminal B
and HER-2 subtypes, respectively (P <0.001), and the
quartile with patients older than 50 years had a positive
CM rate of 42.5% with the HER-2 subtype, which
reached statistical significance (P = 0.001). Thus, younger
age (≤35 years) was not a risk factor for positive CMs in
our study.
The risk of residual disease, including carcinoma in
situ and invasive cancer (residual disease, including car-
cinoma in situ alone, was excluded from one study [39]),
after lumpectomy has been examined in many studies
[24,40]. In recent decades, positive re-excision rates from
17% to 39% have been reported [20,41-43]. In our current
series, 20.3% (209/1,032) of patients had positive CMs, in-
cluding carcinoma in situ and invasive cancer. This result
was similar to those of previously published literature. For
a comprehensive assessment, we also evaluated the posi-
tive CM rate with carcinoma in situ or invasive cancer
alone using multivariate analysis. The positive rates were
9.6% (87/910, CMs with carcinoma in situ alone) and
12.9% (122/945, CMs with invasive cancer alone). For
patients with positive CMs, including carcinoma in
situ, EIC (P <0.001) and BC subtypes (HER-2 vs. luminal
A: P <0.001; luminal B vs. luminal A: P = 0.008; luminal-
HER-2 vs. luminal A: P = 0.032, Table 4) showed a signifi-
cant association with positive CMs. For patients with
positive CMs, including invasive cancer alone, histological
subtype (presence of DCIS component vs. IDC, P = 0.040;
invasive lobular carcinoma vs. IDC, P = 0.031) and pN
stage (N1 vs. N0: P = 0.003; N3 vs. N0: P <0.001, Table 4)
showed statistical correlation with positive CMs. BC
subtype was no longer a relevant factor, which was not
consistent with Sioshansi et al. [39].
There are several inherent limitations to this study.
i) Although many surgeons increasingly prefer to use
CMs for margin assessment, without information from
long-term clinical follow-up, it is not clear whether CMs
or LMs are superior. We used only the CM method with-
out corresponding LM section analysis. ii) This is a single-
center study, and the population was not representative
of Chinese or Asian demographics. iii) BC subtypes ap-
proximated according to ER, PR, HER-2, and Ki67 are only
a substitute for genotype-based molecular BC subtypes.
Jia et al. World Journal of Surgical Oncology 2014, 12:289 Page 8 of 9
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based on these new definitions.
Conclusions
In summary, although there are potential limitations to
this study, the findings showed that that the poor prog-
nosis of the HER-2 subtype is due to increased residual
microscopic tumor burden after lumpectomy. More clin-
ical trials will be required to confirm our conclusion.
This information may help surgeons to choose the most
appropriate surgical treatment for each patient. Further
study and follow-up data are required to confirm the
findings from our study. Oncoplastic breast surgery and
an increased “boost” in radiotherapy may be good choices
for patients with the HER-2 subtype to reduce the micro-
scopic tumor burden and to improve prognosis and
cosmetic results.
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